Sandoz submits ANDA for Tivozanib, marking a new generic entry
Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Tivozanib.
Asset / Drug
Drug and asset intelligence for Tivozanib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
VEGF Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.